JP2020531485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531485A5 JP2020531485A5 JP2020510087A JP2020510087A JP2020531485A5 JP 2020531485 A5 JP2020531485 A5 JP 2020531485A5 JP 2020510087 A JP2020510087 A JP 2020510087A JP 2020510087 A JP2020510087 A JP 2020510087A JP 2020531485 A5 JP2020531485 A5 JP 2020531485A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- trifluoromethyl
- compound according
- methylmorpholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 150000003839 salts Chemical class 0.000 claims 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- -1 methoxy, dimethylamino, trifluoromethylmethoxy Chemical group 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- KIRRPVVLWZDEOM-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-[4-(2-methylpyrazol-3-yl)sulfonyl-2-(trifluoromethyl)piperazin-1-yl]-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)N1C(CN(CC1)S(=O)(=O)C=1N(N=CC=1)C)C(F)(F)F)=O KIRRPVVLWZDEOM-UHFFFAOYSA-N 0.000 claims 2
- YAGDPINTXNUJFA-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-[4-(oxolan-3-ylsulfonyl)-2-(trifluoromethyl)piperazin-1-yl]-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)N1C(CN(CC1)S(=O)(=O)C1COCC1)C(F)(F)F)=O YAGDPINTXNUJFA-UHFFFAOYSA-N 0.000 claims 2
- LTTGFQYAQYEYHW-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-[4-methylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)N1C(CN(CC1)S(=O)(=O)C)C(F)(F)F)=O LTTGFQYAQYEYHW-UHFFFAOYSA-N 0.000 claims 2
- FKHNSGHHGRJGMU-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-[4-pyrrolidin-1-ylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)N1C(CN(CC1)S(=O)(=O)N1CCCC1)C(F)(F)F)=O FKHNSGHHGRJGMU-UHFFFAOYSA-N 0.000 claims 2
- YLNDUJZNLZBUIQ-UHFFFAOYSA-N 6-[4-(2-methoxyethylsulfonyl)-2-(trifluoromethyl)piperazin-1-yl]-4-(3-methylmorpholin-4-yl)-1H-pyridin-2-one Chemical compound COCCS(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)N1C(COCC1)C)C(F)(F)F YLNDUJZNLZBUIQ-UHFFFAOYSA-N 0.000 claims 2
- LMMZDANJUDIECD-UHFFFAOYSA-N 6-[4-(4-fluorophenyl)sulfonyl-2-(trifluoromethyl)piperazin-1-yl]-4-(3-methylmorpholin-4-yl)-1H-pyridin-2-one Chemical compound FC1=CC=C(C=C1)S(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)N1C(COCC1)C)C(F)(F)F LMMZDANJUDIECD-UHFFFAOYSA-N 0.000 claims 2
- AYEISBMTIDMDIW-UHFFFAOYSA-N 6-[4-(5-fluoropyridin-3-yl)sulfonyl-2-(trifluoromethyl)piperazin-1-yl]-4-(3-methylmorpholin-4-yl)-1H-pyridin-2-one Chemical compound FC=1C=C(C=NC=1)S(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)N1C(COCC1)C)C(F)(F)F AYEISBMTIDMDIW-UHFFFAOYSA-N 0.000 claims 2
- MCOXRIXWEFCOLO-UHFFFAOYSA-N 6-[4-[(4-fluorophenyl)methylsulfonyl]-2-(trifluoromethyl)piperazin-1-yl]-4-(3-methylmorpholin-4-yl)-1H-pyridin-2-one Chemical compound FC1=CC=C(C=C1)CS(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)N1C(COCC1)C)C(F)(F)F MCOXRIXWEFCOLO-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000003733 ovarian melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- BPXSDXXWOWIEGU-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-[4-methylsulfonyl-2-(trifluoromethyl)phenyl]-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)C1=C(C=C(C=C1)S(=O)(=O)C)C(F)(F)F)=O BPXSDXXWOWIEGU-UHFFFAOYSA-N 0.000 claims 1
- GEQMLAFCKWRJLD-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-[4-morpholin-4-ylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)N1C(CN(CC1)S(=O)(=O)N1CCOCC1)C(F)(F)F)=O GEQMLAFCKWRJLD-UHFFFAOYSA-N 0.000 claims 1
- VGAYOERTTXJDOP-UHFFFAOYSA-N 4-(3-methylmorpholin-4-yl)-6-[4-piperidin-1-ylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-1H-pyridin-2-one Chemical compound CC1N(CCOC1)C1=CC(NC(=C1)N1C(CN(CC1)S(=O)(=O)N1CCCCC1)C(F)(F)F)=O VGAYOERTTXJDOP-UHFFFAOYSA-N 0.000 claims 1
- YRXRLABGSILYCG-UHFFFAOYSA-N 6-[4-(1,2-dimethylimidazol-4-yl)sulfonyl-2-(trifluoromethyl)piperazin-1-yl]-4-(3-methylmorpholin-4-yl)-1H-pyridin-2-one Chemical compound CN1C(=NC(=C1)S(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)N1C(COCC1)C)C(F)(F)F)C YRXRLABGSILYCG-UHFFFAOYSA-N 0.000 claims 1
- JAVRYPHODLVYTQ-UHFFFAOYSA-N 6-[4-(1-methylcyclopropyl)sulfonyl-2-(trifluoromethyl)piperazin-1-yl]-4-(3-methylmorpholin-4-yl)-1H-pyridin-2-one Chemical compound CC1(CC1)S(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)N1C(COCC1)C)C(F)(F)F JAVRYPHODLVYTQ-UHFFFAOYSA-N 0.000 claims 1
- VUXZPNNEUUVZLC-UHFFFAOYSA-N 6-[4-cyclopropylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-4-(3-methylmorpholin-4-yl)-1H-pyridin-2-one Chemical compound C1(CC1)S(=O)(=O)N1CC(N(CC1)C1=CC(=CC(N1)=O)N1C(COCC1)C)C(F)(F)F VUXZPNNEUUVZLC-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- HJXFEQOSKUTUOT-UHFFFAOYSA-N N,N-dimethyl-4-[4-(3-methylmorpholin-4-yl)-6-oxo-1H-pyridin-2-yl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound CN(S(=O)(=O)C1=CC(=C(C=C1)C=1NC(C=C(C=1)N1C(COCC1)C)=O)C(F)(F)F)C HJXFEQOSKUTUOT-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 0 CC*C(C)=CN(C)C(C)=C Chemical compound CC*C(C)=CN(C)C(C)=C 0.000 description 3
- GHGZGDGWFWIAQM-UHFFFAOYSA-N Cc1c[n](C)nc1C Chemical compound Cc1c[n](C)nc1C GHGZGDGWFWIAQM-UHFFFAOYSA-N 0.000 description 1
- LSZQMSSIUQNTDX-UHFFFAOYSA-N Cc1ccn[n]1C Chemical compound Cc1ccn[n]1C LSZQMSSIUQNTDX-UHFFFAOYSA-N 0.000 description 1
- NSAUQTCATRWAJC-UHFFFAOYSA-N Cc1cnc(C)[o]1 Chemical compound Cc1cnc(C)[o]1 NSAUQTCATRWAJC-UHFFFAOYSA-N 0.000 description 1
- CKQXPRSCSFUGRC-UHFFFAOYSA-N Cc1cncc(F)c1 Chemical compound Cc1cncc(F)c1 CKQXPRSCSFUGRC-UHFFFAOYSA-N 0.000 description 1
- PQISWWYDYOHVJB-BYPYZUCNSA-N F[C@H]1[IH]CCC1 Chemical compound F[C@H]1[IH]CCC1 PQISWWYDYOHVJB-BYPYZUCNSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022198452A JP2023021268A (ja) | 2017-08-23 | 2022-12-13 | モルホリニルピリドン化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187567 | 2017-08-23 | ||
| EP17187567.7 | 2017-08-23 | ||
| PCT/EP2018/072791 WO2019038390A1 (en) | 2017-08-23 | 2018-08-23 | MORPHOLINYLPYRIDONE COMPOUNDS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022198452A Division JP2023021268A (ja) | 2017-08-23 | 2022-12-13 | モルホリニルピリドン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531485A JP2020531485A (ja) | 2020-11-05 |
| JP2020531485A5 true JP2020531485A5 (enExample) | 2021-09-30 |
| JP7199736B2 JP7199736B2 (ja) | 2023-01-06 |
Family
ID=59686888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020510087A Active JP7199736B2 (ja) | 2017-08-23 | 2018-08-23 | モルホリニルピリドン化合物 |
| JP2022198452A Ceased JP2023021268A (ja) | 2017-08-23 | 2022-12-13 | モルホリニルピリドン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022198452A Ceased JP2023021268A (ja) | 2017-08-23 | 2022-12-13 | モルホリニルピリドン化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11560374B2 (enExample) |
| EP (2) | EP3672962B1 (enExample) |
| JP (2) | JP7199736B2 (enExample) |
| KR (1) | KR102732013B1 (enExample) |
| CN (3) | CN111108102B (enExample) |
| AU (2) | AU2018320419B2 (enExample) |
| CA (1) | CA3073142A1 (enExample) |
| CY (1) | CY1125117T1 (enExample) |
| DK (1) | DK3672962T3 (enExample) |
| ES (1) | ES2910157T3 (enExample) |
| HR (1) | HRP20220497T1 (enExample) |
| HU (1) | HUE058661T2 (enExample) |
| IL (3) | IL302077A (enExample) |
| LT (1) | LT3672962T (enExample) |
| PL (1) | PL3672962T3 (enExample) |
| PT (1) | PT3672962T (enExample) |
| RS (1) | RS63109B1 (enExample) |
| SI (1) | SI3672962T1 (enExample) |
| SM (1) | SMT202200169T1 (enExample) |
| TW (2) | TWI803511B (enExample) |
| WO (1) | WO2019038390A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022115562A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
| US20220184093A1 (en) * | 2020-11-25 | 2022-06-16 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of vps34 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2581454A1 (en) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| WO2011058478A1 (en) * | 2009-11-16 | 2011-05-19 | Pfizer Inc. | Substituted triazolopyrimidines as pde8 inhibitors |
| EA201390917A1 (ru) | 2010-12-21 | 2013-12-30 | Новартис Аг | Дигетероарильные соединения в качестве ингибиторов vps34 |
| FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| HUE024504T2 (en) * | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| JP6074043B2 (ja) * | 2013-08-29 | 2017-02-01 | 富士フイルム株式会社 | 新規なモルホリン誘導体またはその塩 |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリール及びその使用 |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| WO2017009751A1 (en) * | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| CA3015045A1 (en) | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| US11179399B2 (en) * | 2016-02-19 | 2021-11-23 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
-
2018
- 2018-08-23 JP JP2020510087A patent/JP7199736B2/ja active Active
- 2018-08-23 AU AU2018320419A patent/AU2018320419B2/en active Active
- 2018-08-23 US US16/639,902 patent/US11560374B2/en active Active
- 2018-08-23 SI SI201830624T patent/SI3672962T1/sl unknown
- 2018-08-23 IL IL302077A patent/IL302077A/en unknown
- 2018-08-23 WO PCT/EP2018/072791 patent/WO2019038390A1/en not_active Ceased
- 2018-08-23 CA CA3073142A patent/CA3073142A1/en active Pending
- 2018-08-23 RS RS20220357A patent/RS63109B1/sr unknown
- 2018-08-23 LT LTEPPCT/EP2018/072791T patent/LT3672962T/lt unknown
- 2018-08-23 HR HRP20220497TT patent/HRP20220497T1/hr unknown
- 2018-08-23 HU HUE18759105A patent/HUE058661T2/hu unknown
- 2018-08-23 PT PT187591052T patent/PT3672962T/pt unknown
- 2018-08-23 EP EP18759105.2A patent/EP3672962B1/en active Active
- 2018-08-23 TW TW107129499A patent/TWI803511B/zh not_active IP Right Cessation
- 2018-08-23 KR KR1020207007564A patent/KR102732013B1/ko active Active
- 2018-08-23 DK DK18759105.2T patent/DK3672962T3/da active
- 2018-08-23 EP EP22153292.2A patent/EP4056569A1/en not_active Withdrawn
- 2018-08-23 PL PL18759105T patent/PL3672962T3/pl unknown
- 2018-08-23 SM SM20220169T patent/SMT202200169T1/it unknown
- 2018-08-23 CN CN201880060742.XA patent/CN111108102B/zh active Active
- 2018-08-23 CN CN202310448740.0A patent/CN116462674A/zh active Pending
- 2018-08-23 ES ES18759105T patent/ES2910157T3/es active Active
- 2018-08-23 CN CN202310448700.6A patent/CN116444510A/zh active Pending
- 2018-08-23 TW TW112116474A patent/TW202348601A/zh unknown
-
2020
- 2020-02-20 IL IL272815A patent/IL272815B/en unknown
-
2022
- 2022-04-14 CY CY20221100283T patent/CY1125117T1/el unknown
- 2022-04-25 IL IL292489A patent/IL292489B2/en unknown
- 2022-12-13 JP JP2022198452A patent/JP2023021268A/ja not_active Ceased
- 2022-12-19 US US18/084,208 patent/US20230234949A1/en not_active Abandoned
-
2023
- 2023-12-22 AU AU2023285995A patent/AU2023285995A1/en not_active Abandoned